🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 21 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 16/12/2013 | 65,68 | 66,64 | 63,91 | 64,76 | -0,64% | 4,16% | 1.212.900 |
| 13/12/2013 | 65,11 | 65,91 | 64,12 | 65,18 | -0,28% | 2,75% | 1.146.500 |
| 12/12/2013 | 64,38 | 66,50 | 64,12 | 65,36 | +1,51% | 3,70% | 1.262.400 |
| 11/12/2013 | 66,12 | 66,23 | 64,18 | 64,39 | -2,78% | 3,10% | 1.195.800 |
| 10/12/2013 | 66,73 | 67,12 | 65,41 | 66,23 | -0,78% | 2,56% | 1.091.300 |
| 09/12/2013 | 66,56 | 66,87 | 65,98 | 66,75 | +0,45% | 1,34% | 1.451.500 |
| 06/12/2013 | 67,13 | 67,28 | 65,77 | 66,45 | +0,00% | 2,25% | 1.240.000 |
| 05/12/2013 | 67,14 | 67,43 | 65,98 | 66,45 | -1,31% | 2,16% | 1.561.600 |
| 04/12/2013 | 67,51 | 68,10 | 66,80 | 67,33 | -0,49% | 1,93% | 1.556.800 |
| 03/12/2013 | 68,81 | 69,04 | 67,32 | 67,66 | -2,30% | 2,50% | 1.646.700 |
| 02/12/2013 | 69,60 | 70,18 | 68,93 | 69,25 | -0,24% | 1,80% | 1.256.700 |
| 29/11/2013 | 68,80 | 70,69 | 68,80 | 69,42 | +1,61% | 2,75% | 957.900 |
| 27/11/2013 | 68,37 | 68,79 | 67,58 | 68,32 | -0,07% | 1,77% | 1.130.200 |
| 26/11/2013 | 68,12 | 68,57 | 67,10 | 68,37 | +0,60% | 2,16% | 2.132.700 |
| 25/11/2013 | 67,44 | 69,00 | 66,75 | 67,96 | +2,53% | 3,34% | 1.566.400 |
| 22/11/2013 | 66,63 | 67,73 | 65,98 | 66,28 | +0,08% | 2,63% | 1.684.700 |
| 21/11/2013 | 65,24 | 66,49 | 65,14 | 66,23 | +1,67% | 2,07% | 1.592.600 |
| 20/11/2013 | 62,53 | 67,69 | 62,39 | 65,14 | +4,42% | 8,48% | 3.471.600 |
| 19/11/2013 | 61,59 | 62,75 | 61,25 | 62,38 | +1,12% | 2,44% | 1.827.200 |
| 18/11/2013 | 63,21 | 63,98 | 61,24 | 61,69 | -2,68% | 4,33% | 2.132.300 |
| 15/11/2013 | 60,87 | 63,42 | 60,87 | 63,39 | +3,87% | 4,19% | 3.083.600 |
| 14/11/2013 | 61,60 | 61,70 | 60,60 | 61,03 | -0,28% | 1,79% | 974.400 |
| 13/11/2013 | 59,83 | 62,13 | 59,14 | 61,20 | +1,69% | 5,00% | 2.560.000 |
| 12/11/2013 | 60,01 | 60,56 | 58,06 | 60,18 | -0,61% | 4,17% | 3.606.400 |
| 11/11/2013 | 61,30 | 61,65 | 60,10 | 60,55 | -0,84% | 2,53% | 2.084.300 |
| 08/11/2013 | 60,86 | 62,25 | 60,42 | 61,06 | +0,05% | 3,01% | 2.187.800 |
| 07/11/2013 | 63,70 | 63,84 | 60,97 | 61,03 | -2,51% | 4,51% | 1.916.200 |
| 06/11/2013 | 65,09 | 65,40 | 61,96 | 62,60 | -4,25% | 5,28% | 4.705.500 |
| 05/11/2013 | 66,11 | 66,83 | 64,95 | 65,38 | -1,25% | 2,84% | 1.903.000 |
| 04/11/2013 | 67,31 | 67,85 | 65,85 | 66,21 | -1,71% | 2,97% | 2.780.900 |